Dr. Shaakir Hasan discusses disparities in bladder cancer diagnosis and treatment
Shaakir Hasan, DO, discusses socioeconomic characteristics associated with the diagnosis and management of bladder cancer.
Shaakir Hasan, DO, New York Proton Center, discusses socioeconomic characteristics associated with the diagnosis and management of bladder cancer. Hasan was the lead author on a research paper shared during the 2021 Genitourinary Cancers Symposium that focused on disparities in bladder cancer. Hasan and his coauthors wrote in their conclusion, "In the largest study of its kind, we report that several socioeconomic, racial, and gender factors are associated with the diagnosis of bladder cancer at a later stage, as well as the use of less cancer-directed treatments” (J Clin Oncol 39, 2021 (suppl 6; abstr 403). doi: 10.1200/JCO.2021.39.6_suppl.403).
Trial launches of MAT2A inhibitor plus sacituzumab govitecan in bladder cancer
June 26th 2024“The MAT2A-Trop2 ADC combination targets 2 distinct, yet complementary nodes in patients with MTAP-deleted urothelial cancer and has first-in-class potential to improve clinical outcomes for bladder cancer patients with poor prognosis associated with MTAP-deletion," says Darrin M. Beaupre, MD, PhD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
